| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | intracellularly calcium-gated channel activity | 5.56e-04 | 20 | 35 | 2 | GO:0141147 | |
| GeneOntologyMolecularFunction | intracellularly calcium-gated chloride channel activity | 5.56e-04 | 20 | 35 | 2 | GO:0005229 | |
| GeneOntologyMolecularFunction | cysteine-type endopeptidase inhibitor activity involved in apoptotic process | 8.04e-04 | 24 | 35 | 2 | GO:0043027 | |
| GeneOntologyMolecularFunction | transforming growth factor beta receptor binding | 1.34e-03 | 31 | 35 | 2 | GO:0005160 | |
| GeneOntologyBiologicalProcess | regulation of G protein-coupled receptor signaling pathway | 1.11e-05 | 181 | 34 | 5 | GO:0008277 | |
| Domain | HECT | 1.71e-05 | 27 | 35 | 3 | PF00632 | |
| Domain | HECTc | 1.71e-05 | 27 | 35 | 3 | SM00119 | |
| Domain | HECT_dom | 1.71e-05 | 27 | 35 | 3 | IPR000569 | |
| Domain | HECT | 1.71e-05 | 27 | 35 | 3 | PS50237 | |
| Domain | WW | 9.24e-05 | 47 | 35 | 3 | PF00397 | |
| Domain | WW | 9.84e-05 | 48 | 35 | 3 | SM00456 | |
| Domain | C2 | 1.02e-04 | 131 | 35 | 4 | PF00168 | |
| Domain | WW_DOMAIN_2 | 1.18e-04 | 51 | 35 | 3 | PS50020 | |
| Domain | WW_DOMAIN_1 | 1.18e-04 | 51 | 35 | 3 | PS01159 | |
| Domain | C2 | 1.22e-04 | 137 | 35 | 4 | SM00239 | |
| Domain | WW_dom | 1.25e-04 | 52 | 35 | 3 | IPR001202 | |
| Domain | C2 | 1.40e-04 | 142 | 35 | 4 | PS50004 | |
| Domain | - | 1.64e-04 | 148 | 35 | 4 | 2.60.40.150 | |
| Domain | C2_dom | 2.43e-04 | 164 | 35 | 4 | IPR000008 | |
| Domain | Kringle | 4.56e-04 | 17 | 35 | 2 | IPR000001 | |
| Domain | Kringle | 4.56e-04 | 17 | 35 | 2 | PF00051 | |
| Domain | KRINGLE_1 | 4.56e-04 | 17 | 35 | 2 | PS00021 | |
| Domain | Kringle_CS | 4.56e-04 | 17 | 35 | 2 | IPR018056 | |
| Domain | KR | 4.56e-04 | 17 | 35 | 2 | SM00130 | |
| Domain | KRINGLE_2 | 4.56e-04 | 17 | 35 | 2 | PS50070 | |
| Domain | Kringle-like | 1.63e-03 | 32 | 35 | 2 | IPR013806 | |
| Pathway | REACTOME_MET_RECEPTOR_ACTIVATION | 6.10e-05 | 6 | 29 | 2 | M27644 | |
| Pathway | REACTOME_MET_RECEPTOR_ACTIVATION | 6.10e-05 | 6 | 29 | 2 | MM15346 | |
| Pathway | PID_TGFBR_PATHWAY | 1.81e-04 | 54 | 29 | 3 | M286 | |
| Pathway | BIOCARTA_EFP_PATHWAY | 4.82e-04 | 16 | 29 | 2 | M22011 | |
| Pathway | KEGG_ENDOCYTOSIS | 4.86e-04 | 181 | 29 | 4 | M1519 | |
| Pubmed | A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. | 5.21e-08 | 8 | 35 | 3 | 19307600 | |
| Pubmed | 1.11e-07 | 10 | 35 | 3 | 25092867 | ||
| Pubmed | 1.53e-07 | 11 | 35 | 3 | 17996703 | ||
| Pubmed | 1.53e-07 | 11 | 35 | 3 | 22773947 | ||
| Pubmed | NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation. | 2.04e-07 | 12 | 35 | 3 | 24107629 | |
| Pubmed | 3.37e-07 | 14 | 35 | 3 | 26147758 | ||
| Pubmed | Assembly and structure of Lys33-linked polyubiquitin reveals distinct conformations. | 5.18e-07 | 16 | 35 | 3 | 25723849 | |
| Pubmed | 6.29e-07 | 17 | 35 | 3 | 28292929 | ||
| Pubmed | 8.95e-07 | 19 | 35 | 3 | 21572392 | ||
| Pubmed | 9.84e-07 | 2 | 35 | 2 | 8631970 | ||
| Pubmed | 9.84e-07 | 2 | 35 | 2 | 31899247 | ||
| Pubmed | 9.84e-07 | 2 | 35 | 2 | 18927080 | ||
| Pubmed | 9.84e-07 | 2 | 35 | 2 | 1838014 | ||
| Pubmed | 9.84e-07 | 2 | 35 | 2 | 15172968 | ||
| Pubmed | 9.84e-07 | 2 | 35 | 2 | 33090007 | ||
| Pubmed | 9.84e-07 | 2 | 35 | 2 | 25998175 | ||
| Pubmed | 9.84e-07 | 2 | 35 | 2 | 18691255 | ||
| Pubmed | 1.23e-06 | 21 | 35 | 3 | 37005481 | ||
| Pubmed | System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes. | 2.39e-06 | 26 | 35 | 3 | 26949039 | |
| Pubmed | 2.95e-06 | 3 | 35 | 2 | 18422749 | ||
| Pubmed | 2.95e-06 | 3 | 35 | 2 | 37537194 | ||
| Pubmed | 2.95e-06 | 3 | 35 | 2 | 21068156 | ||
| Pubmed | The Smurf ubiquitin ligases regulate tissue separation via antagonistic interactions with ephrinB1. | 2.95e-06 | 3 | 35 | 2 | 23475958 | |
| Pubmed | 2.95e-06 | 3 | 35 | 2 | 25051198 | ||
| Pubmed | 2.95e-06 | 3 | 35 | 2 | 11032833 | ||
| Pubmed | 2.95e-06 | 3 | 35 | 2 | 30244169 | ||
| Pubmed | 2.95e-06 | 3 | 35 | 2 | 15173588 | ||
| Pubmed | Requirement of Smurf-mediated endocytosis of Patched1 in sonic hedgehog signal reception. | 2.95e-06 | 3 | 35 | 2 | 24925320 | |
| Pubmed | GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue. | 5.90e-06 | 4 | 35 | 2 | 35192688 | |
| Pubmed | Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis. | 5.90e-06 | 4 | 35 | 2 | 30566427 | |
| Pubmed | 5.90e-06 | 4 | 35 | 2 | 34370213 | ||
| Pubmed | 5.90e-06 | 4 | 35 | 2 | 16373342 | ||
| Pubmed | Nedd8 targets ubiquitin ligase Smurf2 for neddylation and promote its degradation. | 5.90e-06 | 4 | 35 | 2 | 27086113 | |
| Pubmed | 5.90e-06 | 4 | 35 | 2 | 36182093 | ||
| Pubmed | The WW1 Domain Enhances Autoinhibition in Smurf Ubiquitin Ligases. | 5.90e-06 | 4 | 35 | 2 | 31628949 | |
| Pubmed | 9.82e-06 | 5 | 35 | 2 | 28839186 | ||
| Pubmed | Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. | 9.82e-06 | 5 | 35 | 2 | 14722617 | |
| Pubmed | Pivotal role of the C2 domain of the Smurf1 ubiquitin ligase in substrate selection. | 9.82e-06 | 5 | 35 | 2 | 21402695 | |
| Pubmed | 9.82e-06 | 5 | 35 | 2 | 28798345 | ||
| Pubmed | 9.82e-06 | 5 | 35 | 2 | 20937913 | ||
| Pubmed | Inhibition of HECT E3 ligases as potential therapy for COVID-19. | 9.82e-06 | 5 | 35 | 2 | 33762578 | |
| Pubmed | 1.47e-05 | 6 | 35 | 2 | 15252135 | ||
| Pubmed | 1.47e-05 | 6 | 35 | 2 | 21897371 | ||
| Pubmed | 1.47e-05 | 6 | 35 | 2 | 28049720 | ||
| Pubmed | 1.47e-05 | 6 | 35 | 2 | 19318350 | ||
| Pubmed | 1.47e-05 | 6 | 35 | 2 | 22921829 | ||
| Pubmed | 1.47e-05 | 6 | 35 | 2 | 20676133 | ||
| Pubmed | 1.47e-05 | 6 | 35 | 2 | 32361710 | ||
| Pubmed | MST4 negatively regulates type I interferons production via targeting MAVS-mediated pathway. | 1.47e-05 | 6 | 35 | 2 | 35820905 | |
| Pubmed | 1.47e-05 | 6 | 35 | 2 | 23781096 | ||
| Pubmed | CHIP mediates degradation of Smad proteins and potentially regulates Smad-induced transcription. | 2.06e-05 | 7 | 35 | 2 | 14701756 | |
| Pubmed | 2.06e-05 | 7 | 35 | 2 | 30587574 | ||
| Pubmed | SET9-Mediated Regulation of TGF-β Signaling Links Protein Methylation to Pulmonary Fibrosis. | 2.06e-05 | 7 | 35 | 2 | 27292644 | |
| Pubmed | Structure of a ubiquitin-loaded HECT ligase reveals the molecular basis for catalytic priming. | 2.06e-05 | 7 | 35 | 2 | 23644597 | |
| Pubmed | 2.06e-05 | 7 | 35 | 2 | 28169289 | ||
| Pubmed | 2.74e-05 | 8 | 35 | 2 | 28881580 | ||
| Pubmed | Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. | 2.74e-05 | 8 | 35 | 2 | 33930309 | |
| Pubmed | Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain. | 2.74e-05 | 8 | 35 | 2 | 17719543 | |
| Pubmed | 2.74e-05 | 8 | 35 | 2 | 20484049 | ||
| Pubmed | Formin 2 Regulates Lysosomal Degradation of Wnt-Associated β-Catenin in Neural Progenitors. | 3.53e-05 | 9 | 35 | 2 | 29659741 | |
| Pubmed | 4.40e-05 | 10 | 35 | 2 | 15221015 | ||
| Pubmed | 4.40e-05 | 10 | 35 | 2 | 15138260 | ||
| Pubmed | Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. | 7.62e-05 | 13 | 35 | 2 | 36198802 | |
| Pubmed | K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling. | 8.89e-05 | 14 | 35 | 2 | 31015455 | |
| Pubmed | 8.89e-05 | 14 | 35 | 2 | 21791611 | ||
| Pubmed | Identifying the ubiquitination targets of E6AP by orthogonal ubiquitin transfer. | 8.89e-05 | 14 | 35 | 2 | 29263404 | |
| Pubmed | A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase structure-function screen. | 1.17e-04 | 16 | 35 | 2 | 22496338 | |
| Pubmed | A strategy for modulation of enzymes in the ubiquitin system. | 1.33e-04 | 17 | 35 | 2 | 23287719 | |
| Pubmed | PRDM16 determines specification of ventricular cardiomyocytes by suppressing alternative cell fates. | 2.04e-04 | 21 | 35 | 2 | 39304345 | |
| Pubmed | 2.04e-04 | 21 | 35 | 2 | 15328023 | ||
| Pubmed | 2.04e-04 | 21 | 35 | 2 | 23303943 | ||
| Pubmed | USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling. | 2.24e-04 | 22 | 35 | 2 | 24850914 | |
| Pubmed | 2.46e-04 | 23 | 35 | 2 | 15621726 | ||
| Pubmed | Regulation of planar cell polarity by Smurf ubiquitin ligases. | 2.91e-04 | 25 | 35 | 2 | 19379695 | |
| Pubmed | Bmp2 and Notch cooperate to pattern the embryonic endocardium. | 3.15e-04 | 26 | 35 | 2 | 29853617 | |
| Pubmed | 3.66e-04 | 28 | 35 | 2 | 18593464 | ||
| Pubmed | 4.05e-04 | 143 | 35 | 3 | 20424473 | ||
| Pubmed | TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. | 4.20e-04 | 30 | 35 | 2 | 23973329 | |
| Pubmed | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. | 6.09e-04 | 1489 | 35 | 7 | 28611215 | |
| Pubmed | 8.26e-04 | 42 | 35 | 2 | 23444366 | ||
| Pubmed | 9.38e-04 | 191 | 35 | 3 | 33762435 | ||
| Interaction | RNF11 interactions | 1.03e-05 | 169 | 35 | 5 | int:RNF11 | |
| Interaction | TIGIT interactions | 1.21e-05 | 26 | 35 | 3 | int:TIGIT | |
| Interaction | FBXL15 interactions | 1.70e-05 | 29 | 35 | 3 | int:FBXL15 | |
| GeneFamily | Pleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing | 1.83e-05 | 36 | 26 | 3 | 823 | |
| ToppCell | 390C-Lymphocytic-NK_cells-NK_cell_E|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 8.76e-06 | 167 | 35 | 4 | 6c2dade24a88af04b2c90a7e4f8dd7ccea9e94d1 | |
| ToppCell | Control-Myeloid-MoAM2,_CCL18|Myeloid / Condition, Lineage and Cell class | 1.10e-05 | 177 | 35 | 4 | 470f54fe2b21c7350ea471e02039461a3808f700 | |
| ToppCell | 368C-Myeloid-Macrophage-SPP1+_Macrophage_3|368C / Donor, Lineage, Cell class and subclass (all cells) | 1.13e-05 | 178 | 35 | 4 | 536a601abcc60867949ea06e9aafb6c7b799b56b | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.46e-05 | 190 | 35 | 4 | 841cd55861b43578d704418b9bc0af2e8b88323a | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.49e-05 | 191 | 35 | 4 | b13229bb7f3713a392271aaf5dbae3edd1b9fe5a | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.52e-05 | 192 | 35 | 4 | 6f4ef24dab544681304b7f8a9dc073e7edaa4cf5 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.52e-05 | 192 | 35 | 4 | 3d0cb19f037f604253d7d728689aeaa94251e92b | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.52e-05 | 192 | 35 | 4 | deeecd26972241846b4cb998edf0c7a87ff0c4df | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.55e-05 | 193 | 35 | 4 | fb28717fadd06c3840636d25409ce80c9254bd34 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.58e-05 | 194 | 35 | 4 | 60622bd2f75bfe4c37f721cb12f03dab33f2f58d | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuroepithelial|6m / Sample Type, Dataset, Time_group, and Cell type. | 1.78e-05 | 200 | 35 | 4 | 2cc98abf11f5b58707de45a2282f03d47f00f035 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuroepithelial-Proteoglycan-expressing_cell|6m / Sample Type, Dataset, Time_group, and Cell type. | 1.78e-05 | 200 | 35 | 4 | 0f7431f670f3a175377cefae3479403a881bb8fb | |
| ToppCell | control-Myeloid-Monocyte-derived_Macrophage|Myeloid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 2.03e-04 | 146 | 35 | 3 | 69e9c1ec6eec1151290227902e75e77a4aecc8db | |
| ToppCell | droplet-Lung-30m-Hematologic-myeloid-Basophil/Mast_cell-basophil_l14|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.29e-04 | 152 | 35 | 3 | 0fda8980b10ce16179dea92301db74d728f41794 | |
| ToppCell | metastatic_Brain-Fibroblasts-Smooth_muscle_cells|metastatic_Brain / Location, Cell class and cell subclass | 2.96e-04 | 166 | 35 | 3 | 0da2c6ea1e62f1aafabafbbfbbcc6f7011739346 | |
| ToppCell | 5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.01e-04 | 167 | 35 | 3 | 2dc3de562a26077cb76855b725cf278a272d3276 | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-club_cell-Club_(non-nasal)-Club_(non-nasal)_L.0.4.1.3|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.01e-04 | 167 | 35 | 3 | 8fede587572d465cb63f7828141a574185bbb819 | |
| ToppCell | 390C-Lymphocytic-NK_cells-NK_cell_E|NK_cells / Donor, Lineage, Cell class and subclass (all cells) | 3.07e-04 | 168 | 35 | 3 | d8f485f8459532a2cb0bef899e6569142cf75685 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells-NK_cells_L.1.3.1.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.12e-04 | 169 | 35 | 3 | 96aafb687b34d4b59f75c24e176b0b442e864245 | |
| ToppCell | 390C-Myeloid-Macrophage-SPP1+_Macrophage|390C / Donor, Lineage, Cell class and subclass (all cells) | 3.17e-04 | 170 | 35 | 3 | 3a7121d045f9ae54583b0f5f7436abf3665a1bce | |
| ToppCell | Control-Myeloid-MoAM2,_CCL18|Control / Condition, Lineage and Cell class | 3.40e-04 | 174 | 35 | 3 | 4c64ff5666812fb4efa440ba4faeca51d916d68e | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.75e-04 | 180 | 35 | 3 | 08ae0f5d95c45feba68ad99788f7af7ff4c979af | |
| ToppCell | 367C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0.5|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 3.75e-04 | 180 | 35 | 3 | 310a311c3ed924c912a800cf287a825de44b8775 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.75e-04 | 180 | 35 | 3 | 9b1de1b4711adbf9a423f4d2d08f3f4c78f1f8f4 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.81e-04 | 181 | 35 | 3 | 9e7d0f1afb8d9bc5a209ddb5314df3a25a0274d9 | |
| ToppCell | facs-Marrow-T-cells-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.81e-04 | 181 | 35 | 3 | 7286700396676fdc41d9723979b8b408177aceb9 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-Mast-Mast-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.81e-04 | 181 | 35 | 3 | c35ca98c474e31917e0a53c092397e0d8d18b37c | |
| ToppCell | PBMC-Convalescent-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_4|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.81e-04 | 181 | 35 | 3 | 2b9b460239d67fd480cee60820cdb306109d3567 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte-Oligo_L4-6_MOBP_COL18A1|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.81e-04 | 181 | 35 | 3 | a8e9ea73c24109a5d4d28bc0577cc869ad932a4d | |
| ToppCell | PBMC-Convalescent-Myeloid-Classical_Monocyte-Classical_Monocyte-cMono_4|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 3.81e-04 | 181 | 35 | 3 | 2a1aa4a0ec7bc367857beaff543135e4345c835b | |
| ToppCell | droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Mesenchymal-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.81e-04 | 181 | 35 | 3 | 709e9c7a60d5f98635b99895ce30bb87a9f7376d | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.87e-04 | 182 | 35 | 3 | af65f0fc3f9e5d9ce69ee5faaf5b6cb7f8412e0c | |
| ToppCell | NS-moderate-d_16-33-Lymphoid-NK|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 3.87e-04 | 182 | 35 | 3 | fb503f8ecd013f1f2161a5841572b57cfcddb6fa | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.87e-04 | 182 | 35 | 3 | b7d532feb73167e05475855061b35a209583f44c | |
| ToppCell | droplet-Kidney-nan-21m-Mesenchymal-podocyte|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.94e-04 | 183 | 35 | 3 | ad7421623e4c0c5ba02eec56e9bdae43ebb88d90 | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle-MatrixFB_->_Myofibroblast|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.94e-04 | 183 | 35 | 3 | 7eae9b3b4d1c9b135fa7cff348393d4adec474b4 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.94e-04 | 183 | 35 | 3 | 93213124e55d1b673dd345188caf8b5bd31d99fe | |
| ToppCell | droplet-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l44-58|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 3.94e-04 | 183 | 35 | 3 | dc9602bed3136db91faeffef177006246dc92743 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 4.06e-04 | 185 | 35 | 3 | 9f19f04fc4d97dfc2dd78cde77b515f1cb5d51ec | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.06e-04 | 185 | 35 | 3 | 487fa382232564f075960899d50afa0edae5d258 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_2_cell-D231|Adult / Lineage, Cell type, age group and donor | 4.06e-04 | 185 | 35 | 3 | fb6bd7e849ecf4ed9cd9c4e2a946a2d12d62f804 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_adventitial_fibro_(9)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.13e-04 | 186 | 35 | 3 | 8915436d09775f2828a7678af203b1082b36e21c | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.13e-04 | 186 | 35 | 3 | 90eaf6ffb4ce0c34fa1e79f0c8f36f217f44973b | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte-Oligo_L4-6_OPALIN|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.13e-04 | 186 | 35 | 3 | bd8a9753df219084e19e7f94447856e86608325c | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 4.19e-04 | 187 | 35 | 3 | 13731298bc562ec29582f5da1b4c97261284f6f1 | |
| ToppCell | E18.5-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.19e-04 | 187 | 35 | 3 | 3699d5e71d779da922920aa3160895db187bf81b | |
| ToppCell | E18.5-Endothelial-Endothelial_blood-vessel-Microvascular_EC-CAP1-CAP1_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.19e-04 | 187 | 35 | 3 | 033ba52c0c2f9978784947098fa697368ae44834 | |
| ToppCell | P03-Endothelial-large_vessel_endothelial_cell-endothelial_cell_of_artery|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 4.19e-04 | 187 | 35 | 3 | 66ebe1788d51b3e17bec6cdb219f709756b4e530 | |
| ToppCell | P15-Endothelial-large_vessel_endothelial_cell-endothelial_cell_of_artery|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 4.26e-04 | 188 | 35 | 3 | 50b27fc12347ca16bd62333baf345c83cb422a8f | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Oligo|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.26e-04 | 188 | 35 | 3 | d9692b6048d9b85524a07a1807bdd4757731c151 | |
| ToppCell | P07-Endothelial-large_vessel_endothelial_cell-endothelial_cell_of_artery|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 4.26e-04 | 188 | 35 | 3 | 5bc1537e079c7435196c163bff5f639ea392a33a | |
| ToppCell | droplet-Heart-nan-3m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.33e-04 | 189 | 35 | 3 | 8e583ec4df0f5b79ce5211cc99ecd8616d180bde | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.33e-04 | 189 | 35 | 3 | a153b83314cf52808f685296cff8c95af3f4983d | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.33e-04 | 189 | 35 | 3 | 2a22b9fae70afb3dab8476f9c00e48a4df756410 | |
| ToppCell | droplet-Heart-nan-3m-Endothelial-endocardial_endothelial_cells|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.33e-04 | 189 | 35 | 3 | fb2253b8463d08b3d28e952a31a23dea2c2d986b | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.33e-04 | 189 | 35 | 3 | 45e588b2a4ad9e3ff74e22d9d627ed3571f3b8b8 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.39e-04 | 190 | 35 | 3 | 7986586b7c82e91c71102cc8c4d7a689ae63ab4d | |
| ToppCell | Primary_Motor_Cortex_(M1)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte-Oligo_L4-6_MOBP_COL18A1|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.39e-04 | 190 | 35 | 3 | 396b7225c2430db3dc55a3d0db70239b71987229 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.39e-04 | 190 | 35 | 3 | d60395739458d7f47a3350ade751fe3819500320 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.46e-04 | 191 | 35 | 3 | 2110a1dd10730ad7ee7a265fb1716ab3ddafcf4a | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 4.46e-04 | 191 | 35 | 3 | fa380a8752de158974b2ae5e741573439719cc0d | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_adventitial_fibro_(10)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.46e-04 | 191 | 35 | 3 | 156b467187331ac6ca390d6ca861d9670bb7b956 | |
| ToppCell | Control-Stromal_mesenchymal|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.46e-04 | 191 | 35 | 3 | 14057205ddb9b4bbc582d1358d13cf36d979a61b | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.53e-04 | 192 | 35 | 3 | dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708 | |
| ToppCell | LPS_only-Stromal_mesenchymal|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.53e-04 | 192 | 35 | 3 | 162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.53e-04 | 192 | 35 | 3 | bc84b9ce01b4d826a682842ab8a395dac9b91183 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.53e-04 | 192 | 35 | 3 | 4e47a02007f562f29ba5910df64d32a0167d0bd1 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-high_collagen-matrisome_fibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.53e-04 | 192 | 35 | 3 | 0ab1176cfbb0de8dd1f22c6e2c41265cf6c10ee1 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell-D231|Adult / Lineage, Cell type, age group and donor | 4.60e-04 | 193 | 35 | 3 | ef2f456c094e6e3c6ee81e0668c953cb8d0e1c0a | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 4.67e-04 | 194 | 35 | 3 | 8c37bedb23285735ff3828db3889897fada8c95d | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.67e-04 | 194 | 35 | 3 | 6e13549f697f7478b34fe71f7dd9d63c5d3db22e | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_adventitial_fibro_(9)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 4.67e-04 | 194 | 35 | 3 | 5f5f0cdeacd5e1b28717d78dabdb9eb95f661e36 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.67e-04 | 194 | 35 | 3 | 85e00861c5068a27d0cf0ae677f420c8245baa9a | |
| ToppCell | 18-Distal-Mesenchymal-Mesenchyme_SERPINF1-high|Distal / Age, Tissue, Lineage and Cell class | 4.74e-04 | 195 | 35 | 3 | f86737bff21d81673238813df61a15cfe88d0b15 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-Adventitial_fibroblasts_L.2.1.2.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.74e-04 | 195 | 35 | 3 | f54bc4454270ff06e85596f98199372b50d0179f | |
| ToppCell | PCW_05-06-Mesenchymal|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 4.81e-04 | 196 | 35 | 3 | dca52c57ba35d9395cdbca8b881f12ece721b10f | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.81e-04 | 196 | 35 | 3 | 256fe9bc0815f66a9afe11ba3507ef1372b52fd3 | |
| ToppCell | Bronchial-NucSeq-Immune_Myeloid-Mast_cell-Mast_cell|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.88e-04 | 197 | 35 | 3 | bed8a9b73af5caee51b1232b31c24a59353658df | |
| ToppCell | Bronchial-NucSeq-Immune_Myeloid-Mast_cell|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.88e-04 | 197 | 35 | 3 | b7d5073d44aa1e2cb83ea8d8104c5ed662665755 | |
| ToppCell | Bronchial-NucSeq-Immune_Myeloid-Macrophage_other-Macrophage_intermediate|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.88e-04 | 197 | 35 | 3 | e2983ae16c72371fbf0e5c123de9f4d900724e5e | |
| ToppCell | 10x5'v1-week_12-13-Myeloid_macrophage-stroma-stromal_macrophage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 4.88e-04 | 197 | 35 | 3 | 075044c17f1c52008cd3c292c15cbf485b50411e | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c4-CD14-CD16|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.88e-04 | 197 | 35 | 3 | 989eaf7ecef8683e3ec6ec024fd193a2f5861b26 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_1-Subpleural_fibroblasts-Subpleural_fibroblasts_L.2.1.5.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.95e-04 | 198 | 35 | 3 | c66097ae9ba0b50561083c423565665958ef0bb8 | |
| ToppCell | COVID-19-lung-Fibroblast|COVID-19 / Disease (COVID-19 only), tissue and cell type | 4.95e-04 | 198 | 35 | 3 | 3ec01a55ade5e1627258cc3cfebb2c3207a4cb43 | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Proliferative_MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 4.95e-04 | 198 | 35 | 3 | 77c81ec602ab553a544c3d9b1e66181b6f000d12 | |
| ToppCell | Monocytes-Phagocytic_CD16+_macrophages|World / Immune cells in Kidney/Urine in Lupus Nephritis | 4.95e-04 | 198 | 35 | 3 | 09009cc966bf1503c3b15dfa079a6c5f6ad1f507 | |
| ToppCell | Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.95e-04 | 198 | 35 | 3 | 22e766df1276c5b14aa0d83f434f47140ebb98ea | |
| ToppCell | background-Hepatic_Stellate_cells|background / Sample and Cell Type and Tumor Cluster (all cells) | 4.95e-04 | 198 | 35 | 3 | bd11b0e9e80449aab979a02c1023e0638c431c7c | |
| ToppCell | 10x3'2.3-week_12-13-Myeloid_macrophage-stroma-stromal_macrophage|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 4.95e-04 | 198 | 35 | 3 | 9a89083280d4253f282300cdf1e61746d1f32407 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 4.95e-04 | 198 | 35 | 3 | 21cf4d81386761d09d0f6829c01c198e5524176d | |
| ToppCell | Mesenchymal|World / Lineage, Cell type, age group and donor | 5.03e-04 | 199 | 35 | 3 | 4bac110c2b3609f6ee5d0e3275da0824a6240270 | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 5.03e-04 | 199 | 35 | 3 | a7dd94b172c973a131a6792f8ccd9bfe44d984ac | |
| ToppCell | Transverse-Macrophage-LYVE1_Macrophage|Transverse / Region, Cell class and subclass | 5.03e-04 | 199 | 35 | 3 | facf79c256db5ae57bdb613e86ec90616a6f67ca | |
| ToppCell | Transverse-(6)_Macrophage-(61)_LYVE1_Macrophage|Transverse / shred on region, Cell_type, and subtype | 5.03e-04 | 199 | 35 | 3 | dcc2a7f4d1fa30aaaad655dd59c5a2b039d264bf | |
| ToppCell | Parenchymal-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 5.10e-04 | 200 | 35 | 3 | cf433f9b43d7db07acaf70e060f8f77c974e72f3 | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 5.10e-04 | 200 | 35 | 3 | 3dd022e974fec7013ba18f333da63f58fbf2dd7c | |
| ToppCell | 15-Airway|15 / Age, Tissue, Lineage and Cell class | 5.10e-04 | 200 | 35 | 3 | ba4b8d5becf81351901c2ecac74ffa28e29586f3 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 5.10e-04 | 200 | 35 | 3 | 311fab076f2ceb258e3970eb21e39344b894042a | |
| ToppCell | Biopsy_Other_PF-Mesenchymal|Biopsy_Other_PF / Sample group, Lineage and Cell type | 5.10e-04 | 200 | 35 | 3 | d6fcdd48858b53b5a8d18ae14b2dc4d9af41b070 | |
| ToppCell | Neuronal-Inhibitory-iA|Neuronal / cells hierarchy compared to all cells using T-Statistic | 5.10e-04 | 200 | 35 | 3 | 5ef4a3dc18a44292184a59ced916183c0699b01e | |
| Disease | high grade glioma (is_marker_for) | 1.42e-05 | 42 | 33 | 3 | DOID:3070 (is_marker_for) | |
| Disease | vital capacity | 5.04e-05 | 1236 | 33 | 8 | EFO_0004312 | |
| Disease | Liver Cirrhosis, Experimental | 1.93e-04 | 774 | 33 | 6 | C0023893 | |
| Disease | joint hypermobility measurement | 6.27e-04 | 33 | 33 | 2 | EFO_0007905 | |
| Disease | tongue squamous cell carcinoma (is_marker_for) | 7.88e-04 | 37 | 33 | 2 | DOID:0050865 (is_marker_for) | |
| Disease | diet measurement | 9.68e-04 | 1049 | 33 | 6 | EFO_0008111 | |
| Disease | hepatocyte growth factor measurement | 1.11e-03 | 44 | 33 | 2 | EFO_0006903 | |
| Disease | Thrombus | 1.22e-03 | 46 | 33 | 2 | C0087086 | |
| Disease | Thrombosis | 1.38e-03 | 49 | 33 | 2 | C0040053 | |
| Disease | low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 1.44e-03 | 200 | 33 | 3 | EFO_0004611, EFO_0020945 | |
| Disease | risk-taking behaviour | 1.49e-03 | 764 | 33 | 5 | EFO_0008579 | |
| Disease | corpus callosum posterior volume measurement | 1.55e-03 | 52 | 33 | 2 | EFO_0010298 | |
| Disease | factor XI measurement, fibrinogen measurement, tissue plasminogen activator measurement, factor VII measurement | 1.80e-03 | 56 | 33 | 2 | EFO_0004619, EFO_0004623, EFO_0004694, EFO_0004791 | |
| Disease | pyroglutamine measurement | 1.93e-03 | 58 | 33 | 2 | EFO_0005408 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio | 1.94e-03 | 222 | 33 | 3 | EFO_0008317, EFO_0020943 | |
| Disease | C-reactive protein measurement | 1.98e-03 | 1206 | 33 | 6 | EFO_0004458 | |
| Disease | triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement | 2.02e-03 | 225 | 33 | 3 | EFO_0008317, EFO_0020947 | |
| Disease | FEV/FEC ratio | 2.16e-03 | 1228 | 33 | 6 | EFO_0004713 | |
| Disease | arterial stiffness measurement | 2.34e-03 | 64 | 33 | 2 | EFO_0004517 | |
| Disease | aspartate aminotransferase measurement | 3.11e-03 | 904 | 33 | 5 | EFO_0004736 | |
| Disease | monounsaturated fatty acids; 16:1, 18:1 measurement | 3.45e-03 | 78 | 33 | 2 | EFO_0022187 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| WLEDGRELGYAYRAL | 96 | Q99424 | |
| LHGLGWTLRDYVRGY | 206 | Q6ZN30 | |
| ELYGCLWRDGLLSYT | 181 | Q08345 | |
| GFYLRDWILELYGVD | 696 | A5YM72 | |
| SEEGHFRYYLLLGWG | 251 | P48546 | |
| LLCWRGSIYKLLYGE | 21 | O76090 | |
| EISGWYYLLGEHLGR | 251 | P49796 | |
| VSGERLYDWGLRGYI | 161 | Q9BUR5 | |
| WRPYLAYLAGVLGIL | 236 | Q14432 | |
| LYLVLERYLWLLGVG | 256 | Q8TDV5 | |
| EQRWGFGLEELYGLA | 76 | Q9H3P7 | |
| GWGYTGLINYDGLLR | 616 | P14210 | |
| YLYGIISWGDGCGRL | 611 | Q04756 | |
| WELLDRQGAYFYLAG | 536 | Q9UHB4 | |
| GLDYGGVAREWFFLL | 586 | Q96J02 | |
| LDRVGIHGWSYGGYL | 746 | Q6V1X1 | |
| ALLWLLAFYYGPRDG | 421 | Q00597 | |
| NGILLGYEIRYWKAG | 841 | Q02246 | |
| GWLADVYLGRYRAVA | 91 | Q8IY34 | |
| YYGSLGLWLALVDGL | 26 | Q8N2H4 | |
| VLGEGALDRGTYYWE | 471 | Q96LD4 | |
| GAGALYDYGRWLVVV | 141 | P03923 | |
| LGFGRADGEYWLGLQ | 101 | P55083 | |
| RLRPYLGYDWIAGSL | 171 | Q5JXC2 | |
| EGLDYGGVAREWLYL | 436 | Q9HCE7 | |
| GLDYGGVAREWLYLL | 431 | Q9HAU4 | |
| FILATRGLRYWLYGD | 356 | Q9H6R6 | |
| RGLRYWLYGDKILDD | 361 | Q9H6R6 | |
| KWLGHFYGGDCYLLL | 416 | P09327 | |
| GDVGTDLWLALDYYR | 141 | Q5GH73 | |
| ADRLIIIWGAYDGKY | 61 | Q86VZ2 | |
| WANGIYLVCGRLYGL | 1861 | Q9UGU0 | |
| LYGAVAERLWEYGFL | 441 | Q8IWY8 | |
| LSGGGDWHIAYVLLY | 466 | P54578 | |
| DWYRWLGYLGLLLLD | 206 | Q9C0H2 | |
| VVAFLGGLDLAYGRW | 451 | O14939 | |
| GGLDLAYGRWDDLHY | 456 | O14939 | |
| YDEGCDIWSLGILLY | 591 | Q15418 |